Kaunas, Lithuania / Istanbul, Turkey – August 4, 2025.
Biomapas, a global contract research organization (CRO) serving the pharmaceutical and biotechnology industries, today announced the acquisition of Delta PV, a leading pharmacovigilance service provider headquartered in Istanbul, Turkey. The strategic move expands Biomapas’ global safety capabilities and strengthens its presence in high-growth regions, including Europe, the Commonwealth of Independent States (CIS), Asia-Pacific (APAC), and the Middle East and North Africa (MENA).
Delta PV brings trusted global expertise in pharmacovigilance, offering end-to-end support from QPPV services to literature screening, signal detection, and compliance. Powered by its proprietary automated platform, Delta PV streamlines safety data monitoring—delivering a seamless, compliant, and digitally enabled solution for today’s fast-paced life sciences environment.
“This acquisition marks an exciting milestone in Biomapas’ growth journey,” said David Passov, CEO of Biomapas. “By integrating Delta PV’s scientific expertise and technology, we are further equipping our team to support clients in navigating an increasingly complex regulatory environment. We’re thrilled to welcome Delta PV’s highly skilled professionals into the Biomapas family.”
Delta PV has earned a strong reputation for its science-driven and client-centric approach to pharmacovigilance, supporting a wide range of pharmaceutical and biotechnology clients. Both companies remain fully committed to delivering uninterrupted, high-quality services to all clients.
“We are proud to join forces with Biomapas, an organization that shares our dedication to innovation, quality, and patient safety,” said Aytek Dağıstanlı, CEO of Delta PV. “This partnership will allow us to scale our solutions and continue delivering outstanding value to our clients across global markets.”
In October 2024, Carbyne Equity Partners became a strategic shareholder in Biomapas with the goal of accelerating the company’s global growth. The acquisition of Delta PV marks the first strategic step following this partnership and reflects the shared ambition to scale Biomapas’ services in key markets.
“Delta PV brings deep regional knowledge, scientific strength, and additional digital capabilities to Biomapas. This partnership reflects the ambition we share — to build a truly global platform in pharmacovigilance and life sciences services,” said Alexander Winterling, Chairman of the Board at Biomapas and Managing Partner at Carbyne Equity Partners.
For more information:
communication@biomapas.com
About Biomapas
Biomapas is a pan-European pharmaceutical services provider offering tailored solutions in clinical trials, pharmacovigilance, medical information, regulatory affairs, and medical writing. Headquartered in Lithuania, Biomapas supports biotechnology, pharmaceutical, and medical device clients across the globe, combining global standards, local expertise, and technology-driven efficiencies. Learn more at www.biomapas.com.
About Delta PV
Delta PV is a globally active pharmacovigilance service provider headquartered in Istanbul, Turkey. The company offers expert safety monitoring services, including Qualified Person for Pharmacovigilance (QPPV), literature screening, and signal management. Known for its proactive approach and tailored pharmacovigilance solutions, Delta PV supports pharmaceutical and biotechnology clients across MENA, APAC, CIS, and European regions. Learn more at www.deltapv.com.
About Carbyne Equity Partners
Carbyne Equity Partners is a leading European private equity firm with a focus on R&D driven businesses in the healthcare, nutrition, and agricultural technology sector. Carbyne is backed by a globally operating and family-owned German company in the life sciences sector. Learn more at www.carbynepartners.de
